Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prodarsan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| oral, liquid solution | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Prodarsan | DRUG | Prodarsan TID, oral solution, 6-8 days |
Inclusion Criteria: * Parents or legal guardian(s) of the pediatric patient with CS must be willing and able to give written Informed Consent. Informed Assent will be offered to children who can understand and participate in the Informed Assent process. * Diagnosis of CS confirmed by one of the fol...
Prodarsan is an investigational small molecule developed by Pharming Group N.V. for Cockayne Syndrome, a rare inherited disorder. It is in Phase 1 clinical development and has been studied in a single completed trial. Prodarsan is not approved for commercial use.
Prodarsan is being developed as a treatment for Cockayne Syndrome, a rare genetic disorder. It has been evaluated in a Phase 1 study in patients with this condition. The drug remains investigational and is not approved for any indication.
Prodarsan is developed by Pharming Group N.V., a biopharmaceutical company whose shares trade under the ticker PHAR. Pharming is the sponsor of the clinical program evaluating Prodarsan in Cockayne Syndrome.
Prodarsan is in Phase 1 clinical development. The program includes one completed Phase 1 trial, and no active trials are currently listed. Prodarsan is investigational and has not been approved by the FDA.
Prodarsan has been studied in one completed Phase 1 trial, NCT01142154, titled a pharmacokinetics and safety study of single and multiple oral doses in patients with Cockayne Syndrome. The trial enrolled 5 patients in the United States and was uncontrolled, with no randomization or blinding.